{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:01:44Z","timestamp":1792008104634,"version":"4.4.0"},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":1984,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:p>This multicenter, open\u2010label study evaluated pharmacokinetics, pharmacodynamics, and safety of agalsidase alfa in pediatric compared with adult patients with Fabry disease. The pharmacokinetic parameters of pediatric patients (19 boys, 5 girls, 6\u201318 years old; mean age, 11.8 years) were compared to those of adult male and female patients who participated in other clinical studies. All patients received agalsidase alfa at a dose of 0.2 mg\/kg infused over 40 minutes every other week. Agalsidase alfa exhibited a biphasic serum elimination profile with a maximum serum concentration at the end of the 40\u2010minute infusion; &lt;1% of the maximum concentration was detected 8 hours after dosing. In children, serum clearance was 2.0 to 9.4 mL\/min\/kg and tended to decrease with increasing age. The average clearance in children, 3.7 \u00b1 1.5 mL\/min\/kg (mean \u00b1 SD), was significantly greater than that measured in 33 adults (2.3 \u00b1 0.7 mL\/min\/kg<jats:sup>1<\/jats:sup> <jats:italic>P<\/jats:italic> &lt; .0001). Mean terminal elimination half\u2010life of agalsidase alfa was prolonged in week 25 compared with baseline (150 vs 66 minutes) in 8 of 19 male children. The magnitude of the reduction of plasma globotriaosylceremide was similar in all age groups and was independent of area under the curve and other pharmacokinetic parameters. Except for clearance in younger patients, agalsidase alfa appears to have comparable pharmacokinetic and pharmacodynamic profiles in pediatric and adult Fabry patients of both genders.<\/jats:p>","DOI":"10.1177\/0091270007305299","type":"journal-article","created":{"date-parts":[[2007,8,14]],"date-time":"2007-08-14T00:40:30Z","timestamp":1187052030000},"page":"1222-1230","source":"Crossref","is-referenced-by-count":35,"title":["Enzyme Replacement in Fabry Disease: Pharmacokinetics and Pharmacodynamics of Agalsidase Alfa in Children and Adolescents"],"prefix":"10.1002","volume":"47","author":[{"given":"Markus","family":"Ries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe T.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Whybra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S.","family":"Loveday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roscoe O.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Schiffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196705252762101"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.20.4.309"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000016684.07368.75"},{"key":"e_1_2_5_5_2","first-page":"109","article-title":"Renal ultrastructural findings in Anderson\u2010Fabry disease","volume":"15","author":"Sessa A","year":"2002","journal-title":"J Nephrol"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.38.11.750"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200203000-00003"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2004.01309.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-003-1299-3"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-1678"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.38.11.769"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012993305223"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2004.00219.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450102"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2743"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10497"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000091253.71282.04"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:BOLI.0000005658.14563.77"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-282X2006000500002"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfi152"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/422366"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-2895"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:BOLI.0000009948.86528.72"},{"key":"e_1_2_5_24_2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0021-9258(19)69965-5","article-title":"Affinity purification of a\u2010galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination: properties of the purified splenic enzyme compared to other forms","volume":"256","author":"Bishop DF","year":"1981","journal-title":"J Biol Chem"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.1.365"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwg034"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cccn.2004.10.019"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.61.070192.001515"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4157(95)00004-B"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197307052890103"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118617"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840210515"},{"key":"e_1_2_5_33_2","first-page":"79","volume-title":"Handbook of Pediatrics","author":"Silver HK","year":"1980"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270007305299","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270007305299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T05:55:01Z","timestamp":1697090101000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270007305299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1177\/0091270007305299"],"URL":"https:\/\/doi.org\/10.1177\/0091270007305299","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}